Projects

Click4PET

Batch: Spring 2026

A rapid, microfluidic technology enabling efficient F-18 radiolabeling of biomolecules for PET imaging.

Contact person: Khalil Elbadri

BodyWatch

Batch: Spring 2026

We are developing a novel wearable device for continuous unobstructive monitoring of blood pressure, detecting cardiovascular events, and multimodal physiological monitoring.

Contact person: Ivan Zubarev

SISGA

Batch: Spring 2026

A simple, mobile, clinically accurate gait and running analysis system that uses wearable sensors and AI to deliver objective, real-time movement assessment and rehabilitation support.

Contact person: Mikko Salminen

LOUHI

Batch: Spring 2026

LOUHI is developing biofilm-disrupting compounds to make chronic lung infections—especially those from nontuberculous mycobacteria—easier to treat, aiming for shorter therapy and less antimicrobial use.

Contact person: Milka Hammarén

VESTI

Batch: Spring 2026

Vesti develops a new method to assess peripheral vertigo and vestibular disorders.

Contact person: Kai Kronströmﾠ

ExoscopeTwin

Batch: Spring 2026

Digital twin platform for exoscopic surgical systems research and development, regulatory compliance, and training.

Contact person: Martin Lehecka

PeptiBlock

Batch: Spring 2026

Developing biologic therapeutics to selectively block pathological blood vessel leakage, guided by unique insight into vascular signaling to improve health resilience.

Contact person: Pipsa Saharinen

RecombiGel

Batch: Spring 2026

Customizable hydrogel platforms powering future biomedical innovation.

Contact person: Austin Donnelly Evans

UltraPlex

Batch: Spring 2026

UltraPlex develops a next-generation, scalable, and sustainable liposome-based delivery platform for RNA therapeutics.

Contact person: Sanjeev Ranjan

IndiviChip

Batch: Fall 2025

Automated microfluidic platform for activity-based screening of extracellular biomarkers

Contact person: Tiina Sikanen

ICDx – Next-Generation Immunoassays for Hormone Diagnostics

Batch: Fall 2025

Highly sensitive and scalable immunoassay platform enabling accurate hormone testing for both centralized laboratories and future point-of-care applications

Contact person: Teppo Hyytiä

GenesMAP

Batch: Fall 2025

γPNA/MNAzyme as a new tool for rapid and sensitive gene detection in double-strand DNA

Contact person: Hongbo Zhang

MIOR Immunotherapy

Batch: Fall 2025

Developing new immunotherapies for cancer

Contact person: Carlos Rogerio Figueiredo

Orca

Batch: Spring 2025

Modernizing computer-assisted joint replacement surgery with a novel camera-based system

Contact person: Ville Pitkänen & Taneli Tikkakoski

Brain-Informed

Batch: Spring 2025

From traditional to neurophysiology-guided stroke rehabilitation — we are creating a tool to individualize motor rehabilitation based on each patient's unique functional brain reserve.

Contact person: Miikkael Salmi

AdCab

Batch: Spring 2025

We are targeting pancreatic cancer's Achilles heel with a groundbreaking and novel mechanism

Contact person: Tuuli Ranki & Firas Hamdan

Kudos – Cellular Twins

Batch: Spring 2025

We aim to create AI models that can diagnose diseases and predict drug efficacy from early-phase histological biopsies based on cellular morphology, whilst avoiding the need for expensive and time-consuming drug assays.

Contact person: Minttu Polso

Symptonic

Batch: Spring 2025

Developing an AI algorithm to remotely detect and monitor health indicators through analysis of speech signals

Contact person: Mikko Petäjä

B1 Coils

Batch: Spring 2025

Next generation radiofrequency coils to acquire more data from each MRI scan, enhancing diagnostic and treatment precision.

Contact person: Denis Le Bras

PreMet

Batch: Spring 2025

We develop a rapid, accurate, and predictive diagnostic platform for early-stage breast cancer and its metastasis.

Contact person: Nonappa

Stop Seizures

Batch: Spring 2025

Stop Seizures project aims to develop a novel drug with a unique drug target for treating Epilepsy.

Contact person: Svetlana Sharifulina

MyNeuroCure

Batch: Fall 2024

A novel & ground-breaking drug therapy for ALS

Contact person: Merja Voutilainen

DropByeDrop

Batch: Fall 2024

Simplifying Glaucoma Care: Monthly Eyedrops for Improved Patient Compliance

Contact person: Stanislav Kalinin

Cornea Sense

Batch: Fall 2024

Cornea health diagnostic by directly measuring cornea hydration levels for better patient outcomes and treatment
Spin-out to Cornea Sense Oy

Contact person: Anton Chernenko

LimbMate

Batch: Fall 2024

A stand that allows easier casting and better performance in limb procedures.
(Link in Finnish)

Contact person: Pekka Nätti

NeuroEye Insight

Batch: Spring 2024

Opportunistic Screening of Alzheimer's Disease Using Retinal Imaging

Contact person: Sebastian Högnabba

DepMYC

Batch: Spring 2024

Developing MYC-dependency targeting drugs to treat cancer

Contact person: Juha Klefström

PREPARE

Batch: Spring 2024

Development of powerful protein-based vaccine technologies
Spin-out to Innofend Oy

Contact person: Minna Hankaniemi

OxyBioStroke

Batch: Spring 2024

A blood test for fast track to stroke treatment

Contact person: Helike Lõhelaid

ERresQ

Batch: Spring 2024

Development of novel cellular stress regulators for the treatment of neurological and metabolic diseases.
Spin-out to ERresQ Oy

Contact person: Vera Kovaleva

Im.Engine

Batch: Spring 2024

Pocket sized microscope that solves the challenges faced by research and diagnostic labs.
Project manager was recruited to key position at Zero Gravity Oy

Contact person: Igor Shevkunov

BioS3nse

Batch: Fall 2023

Graphene oxide platform for biosensor development

Contact person: Juha Huiskonen

KAJO Neurotechnologies

Batch: Fall 2023

Developing pathophysiologically relevant in vitro models for human neurodegenerative disorders for drug discovery
Turned into a drug development project.

Contact person: Mikko Airavaara

TrueScreen

Batch: Fall 2023

A novel, non-invasive approach for cancer screening and diagnosis

Contact person: Andrew Erickson

MIND’S EYE

Batch: Fall 2023

Diagnostics of developmental conditions with eye tracking

Spin-out to Mind's Eyetrack Oy

Contact person: Anna Ptukha

NAVIGATOR

Batch: Fall 2023

Developing and new tumour-specific agent designed to diagnose and treat metastatic brain tumours.

Contact person: Pirjo Laakkonen

Solid-IO

Batch: Fall 2023

Cancer immunotherapy testing on a chip.
Spin-out to Solid Immuno-Oncology Oy

Contact person: Heidi Haikala

Immunoliposomes

Batch: Spring 2023

Immunoliposomes to detect rupture prone intracranial aneurysms

Contact person: Behnam Rezai Jahromi

Feanalytic

Batch: Spring 2023

Non-invasive method to diagnose intestinal diseases

Contact person: Lauri Polari

Vit3DAct

Batch: Spring 2023

Intra-articular calcipotriol for treatment of (osteo)arthritis

Contact person: Johanna Huhtakangas

Natal Mind

Batch: Spring 2023

Digital therapeutics treatment for fear of childbirth

Contact person: Annika Järvelin

Colorific

Batch: Spring 2023

DNA Nanoswitches-enabled Visual Colorimetric Diagnostics.
Spinoff to be established

Contact person: Jacky Loo

Glue4Life

Batch: Spring 2023

Next-generation bioinks for 3D bioprinting living tissues and organs.
Spin-out to LifeGlue Technologies Oy

Contact person: Anni Mörö

SanguID

Batch: Spring 2023

Improved early-stage cancer detection and sensitive disease monitoring
Project manager moved to University of Zurich.

Contact person: Pyry Helkkula

OTOS

Batch: Spring 2023

Early intervention for hearing health
Spin-out to Otos Health Oy

Contact person: Tanja Tervonen

INGA

Batch: Spring 2023

Novel method for optimized and personalized labor induction care
Spin-out to Inga Health Oy.

Contact person: Hanna Castrén-Niemi

Incight (Jedi R2B)

Batch: Fall 2022

A smart optical sensor for arthroscopic surgery
Spin-out to Incight Medical Technologies Oy

Contact person: Isaac Afara

Mukava

Batch: Fall 2022

Graphene based dry electrodes for biometric measurements
Spin-out to Mukava Biosignals Oy

Contact person: Teemu Ruotsalainen

R2therapies

Batch: Fall 2022

Novel biomarker and early drug intervention for Alzheimer's disease

Spin-out to R2therapies Oy

Contact person: Ilkka Fagerlund

Surgerix

Batch: Fall 2022

(Former ER4Surgery) Image-guided surgery without Instruments.
Spin-out to Surgerix Oy.

Contact person: Mikko Pitkänen

3D CelluGel

Batch: Fall 2022

A Novel Cell Growth Matrix by 3D Printing of Biopolymers

Contact person: Chunlin Xu

TrueHear

Batch: Spring 2022

Digital hearing diagnostics

Contact person: Aarno Dietz

L-Cell

Batch: Spring 2022

Light- reconfigurable substrate for cell cultures.
Project manager was recruited to another big project at Tampere University.

Contact person: Chiara Fedele

Brightlife

Batch: Spring 2022

Mental health platform and services

Spin-out to Brightlife Oy

Contact person: Eero Haikonen

COMITELL

Batch: Spring 2022

Delivery of encapsulated mitochondria as novel pharmaceutical solution.
Spinoff to be established.

Contact person: Oliver Koivisto

Multivision Diagnostics

Batch: Spring 2022

Automated and scalable tool for precision diagnosis and personalized treatment
Spin-out to MultivisionDx Oy

Contact person: Karolina Punovuori

AIDHEART

Batch: Fall 2021

AI for the detection of heart transplant rejection.
Product validation continues, spin-out under consideration.

Contact person: Juha Peltonen

PAMO

Batch: Fall 2021

Novel method for diagnosing respiratory suppression
Spin-out to Brecas Oy

Contact person: Antti Vehkaoja

hentoTouch

Batch: Fall 2021

Non-invasive solution to support rehabilitation from AUD.
Spin-out to AlionLife Oy

Contact person: Jukka Planman

Urisens

Batch: Fall 2021

Diaper embedded biosensor platform, that screens abnormal clinical conditions

Contact person: Oguz Tanzer

Nosore

Batch: Fall 2021

Prevention of pressure ulcers
Manager was recruited as Team Leader to Attendo.

Contact person: Nuno Nobre

OrganAnalytics

Batch: Fall 2021

Viability analysis of organ transplants, and neuronal and cardiac implants
Preparing spin-out to a startup.

Contact person: Jarno Tanskanen

TumorMimic

Batch: Fall 2021

TumorMimic tailors 3D cultures to enable enhanced cancer drug screening

Contact person: Juho Pokki

GLOBEVAC

Batch: Fall 2021

How to make vaccines thermostable
Spin-out to GlobeVAC Oy.

Contact person: Manlio Fusciello

Proteabs

Batch: Spring 2021

Rapid diagnostics of human picornaviruses based on viral proteases

Contact person: Petri Susi

3DFluoHisto

Batch: Spring 2021

Novel method for histology.
Solution for commercial use at University of Turku.

Contact person: Ilkka Paatero

mTMS

Batch: Spring 2021

mTMS – multilocus transcranial magnetic stimulation.
Spin-out to Cortisys Oy.

Contact person: Dubravko Kicic

Corflux

Batch: Spring 2021

Personalized prediction of the risk for aortic dilatation and rupture.
Preparing spin-out to a startup.

Contact person: Marja Hedman

JasminePro

Batch: Spring 2021

Poly(jasmine lactone): A Versatile Platform for Drug Delivery

Contact person: Kuldeep Bansal

MAIJU

Batch: 2020

Method for objective assessment of infant motor development.
Solution in use at BABA Center (HUS) and collaboration with Movesense.

Contact person: Sampsa Vanhatalo

DecoDerma

Batch: 2020

Tissue specific therapy for skin diseases.
Licensed to THERAVIA.

Contact person: Tero Järvinen

Integrated Secretion Solutions

Batch: 2020

Platform for optimized production of biotechnological proteins

Spin-out to Avenue Biosciences Oy and a startup in the U.S.

Contact person: Ville Paavilainen

MEG-MRI

Batch: 2020

Functional brain imaging reshaped

Contact person: Marko Havu

Wittify

Batch: 2020

Smart heart monitoring.

Spin-out to Sonai Health Oy.

Contact person: Arto Kotimaa

EpiHeart

Batch: 2020

Cardiac Micrograft Therapy™ for treating Ischhemic Scars and Heart Failure.

Spin-out to EpiHeart Oy.

Contact person: Kai Kronström

AccuQT

Batch: 2020

Accurate correction for QT interval ‒ the most important cardiac risk measure.
Spin-out to Monicardi Oy

Contact person: Esa Räsänen

Capsamedix

Batch: 2020

Long-term oral drug delivery.

Alumni due Prof. Helder Santos got recruited as Head of Biomedical Engineering at UMCG (Groningen, NED).

Contact person: Helder Santos

Anison

Batch: 2020

Natural medication for human papillomavirus (HPV)-associated warts.

Spin-out to ATB Antivirals Oy

Contact person: Preethy Paul

Moncyte

Batch: 2020

Functional insight into hypercholesterolemia patients.
Spin-out to Moncyte Oy

Contact person: Simon Pfisterer

Algoa Progress

Batch: 2020

Personalized treatment planning of osteoarthritis.

Spin-out to MSK Technologies Oy.

Contact person: Joona Kemppainen

Solving the Mesh

Batch: 2020

Implantable support to treat pelvic organ prolapse.
Spin-out to Lignum Medical Oy

Contact person: Eija Raussi-Lehto

TOXELEGANS

Batch: 2020

Indoor air diagnostics with fluorescent C. elegans nematodes.

Lead to a co-research project.

Contact person: Päivi Koskinen

StemSight

Batch: 2019

Novel treatment for limbal epithelial stem cell deficiency.

Spin-out to StemSight Oy

Contact person: Laura Koivusalo

VIRI

Batch: 2019

Therapeutics for antimicrobial resistant bacteria.

Spin-out to Arivin Therapeutics Oy, was accepted to INCATE Incubator.

Contact person: Christopher Jonkergouw

FRACTAID

Batch: 2019

Distal radius fractures artificial intelligence diagnostic tool.
Preparations for a startup in progress.

Contact person: Jorma Ryhänen

AdvaNeedle

Batch: 2019

Ultrasound solution for cancer biopsies
Technology licensing under preparation.

Contact person: Jouni Rantanen

DropPen

Batch: 2019

Simple droplet devices for biomedicine, diagnostics and pharma.
Got continuing development funding.

Contact person: Päivi Saavalainen

VertiGoggles

Batch: 2019

Vertigo diagnostics for primary care.

Got remarkable funding for another project.

Contact person: Tuomas Hyytiä

NADMed

Batch: 2019

Diagnostic test for vitamin B3 metabolism deficiency.

Spin-out to NADMED Oy

Contact person: Liliya Euro

TopoCoating

Batch: 2019

Topographically tuned and sustainable surfaces for biological applications.

Potential licensing case. Project manager got recruited as Innovation Manager at UTU.

Contact person: Erik Niemelä

Liquid Biopsy Solutions

Batch: Fall 2018

Laboratory and computational method for liquid biopsies.
Spin-out to Genomill Health Oy

Contact person: Manu Tamminen

PPI Modulators

Batch: Fall 2018

Rational discovery of protein-protein interaction modulators.

Spin-out to Aurlide Oy

Contact person: Olli Pentikäinen

PARKS – Parkinson’s Biomarker Test

Batch: Fall 2018

Parkinson’s signature biomarker assay.
Ongoing large validation study with Michael J Fox Foundation funding.

Contact person: Eleanor Coffey

LightReactor

Batch: Spring 2018

Light controlled protein production.
An alumni due Project Manager got recruited to Bayer.

Contact person: Jari Rossi

Team Scheperjans

Batch: Spring 2018

Microbiome therapy for Parkinson’s disease.
IP turned into NeuroBiome Oy that has contract with a large company

Contact person: Filip Scheperjans

HemoCure

Batch: Spring 2018

Extra cellular vesicle solution for bleeding disorders.
An alumni due Project Manager got recruited to Mayo Clinic (USA).

Contact person: Mayank Saraswat

FastEV

Batch: Spring 2018

Method for extra-cellular vesicle (EV) isolation.
Solution in use at EV group at University of Helsinki.

Contact person: Maija Puhka

Heart4Oxygen

Batch: Spring 2018

Method to monitor the oxygenation of myocardial tissue.
Spin-out to SpectroCor Oy

Contact person: Kalle Kotilahti

Maculaser

Batch: Spring 2018

Novel heat treatment for age related macular degeneration.
Spin-out to Maculaser Oy

Contact person: Jani Tirronen

Team Scheperjans

Batch: Spring 2018

Microbiome diagnostics for Parkinson’s disease.
IP turned to NeuroBiome Oy that has joint development and licensing agreement.

Contact person: Filip Scheperjans

TB Biofilm

Batch: Spring 2018

Mycobacterial biofilms as anti-tuberculosis drug targets.
Became a cornerstone of an extensive multinational research program.

Contact person: Mataleena Parikka

SCELLOMICS

Batch: Spring 2018

Novel single cell omics methods.
Spin-out to Scellex Oy

Contact person: Päivi Saavalainen

LASU

Batch: Spring 2018

Light-activated antimicrobial surfaces and materials.
IP acquired by Plasmonics Oy

Contact person: Alexandre Efimov

NEXTCAST

Batch: Fall 2017

AI solution for toxicity testing.

Solution in use at FHAIVE, a reference toxicity laboratory for EURL ECVAM.

Contact person: Dario Greco

EyeLase

Batch: Fall 2017

Laser solution for eye treatment.

Became a development case for industry.

Contact person: Jukka Viheriälä

HuManCardio

Batch: Fall 2017

Toxicity test for heart cells.

Solution in use at FHAIVE, a reference toxicity laboratory for EURL ECVAM.

Contact person: Tuula Heinonen

Olfactomics

Batch: Fall 2017

Tissue analysis for breast cancer surgery.
Spin-out to Olfactomics Oy

Contact person: Antti Roine

Ocular Surface Precision Panel

Batch: Spring 2017

Ocular biomarker panel and analysis.
Project manager got recruited to another project.

Contact person: Ulla Aapola

GreenSeq/ Seqnom

Batch: Spring 2017

Microbiological Analyses on (Blue) Bio- and Circular Economies.
Spin-out to GreenSeq Oy

Contact person: Kirsi-Maarit Lehto

SMART PD

Batch: Spring 2017

Peritoneal diagnostics for dialysis patients.
Spin-out to Kiwecare / Smart PD Solutions Oy

Contact person: Pirgit Silvast-Äikäs

SEBI-Group

Batch: Pilot 2016 / Spring 2017

Nano structure for bioimaging.
Spin-out to XFold Imaging Oy

Contact person: Timo Jäntti

Sartar

Batch: Pilot 2016 / Spring 2017

Cancer drug for GIST.
Spin out to Sartar Therapeutics Oy

Contact person: Harri Sihto

iDenta

Batch: Pilot 2016 / Spring 2017

Caries and infection prevention and treatment.

Spin-out to Koite Health Oy

Contact person: Tommi Pätilä

Surgify

Batch: Pilot 2016 / Spring 2017

Safety mechanism for surgical drills.

Spin-out to Surgify Medical Oy

Contact person: Visa Sippola